Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chemotherapy regimens

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    787 result(s) found for: Chemotherapy regimens. Displaying page 7 of 40.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2005-000558-60 Sponsor Protocol Number: PX104.1.7-202 Start Date*: 2005-06-02
    Sponsor Name:Pharmexa A/S
    Full Title: A Phase II trial evaluating the immunological and clinical efficacy and safety of HER-2 Protein AutoVac(TM) and Stimulon® Adjuvant QS-21 monotherapy in patients with metastatic breast cancer
    Medical condition: Female patients with histologically proven metastatic or locally advanced breast cancer who have HER-2 overexpression in the primary tumour and/or a metastatic lesion.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006055-33 Sponsor Protocol Number: HypoGI Start Date*: 2023-03-05
    Sponsor Name:Medical University of Vienna
    Full Title: Assessing the feasibility of pharmacologically induced hypothyroidism in patients with advanced pancreatic cancer - a pilot study
    Medical condition: Patients with newly diagnosed metastatic pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003791-23 Sponsor Protocol Number: I4T-MC-JVDB Start Date*: 2015-04-23
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I4T-MC-JVDB Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second Line Gastric or Gastroesophageal Junction Adenocarcinoma
    Medical condition: Second Line Gastric or Gastroesophageal Junction Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) FR (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2012-003481-41 Sponsor Protocol Number: FM-12-B01 Start Date*: 2013-02-19
    Sponsor Name:FONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI
    Full Title: Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-negative high-risk breast cancer ETNA (Evaluating Treatment with Neoadjuvant Abraxane)
    Medical condition: Patients with HER2-negative, early invasive unilateral breast cancer who are at risk of disease recurrence and suitable for neoadjuvant chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10006283 Breast neoplasm malignant female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended) DE (Completed) ES (Completed) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001013-16 Sponsor Protocol Number: PRODIGE69 Start Date*: 2020-07-20
    Sponsor Name:CHU DIJON
    Full Title: FOLFIRINOX VERSUS PLATINUM - ETOPOSIDE AS FIRST LINE CHEMOTHERAPY FOR METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF GASTRO ENTERO PANCREATIC AND UNKNOWN PRIMARY ASSOCIATED WI...
    Medical condition: METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF GASTRO ENTERO PANCREATIC AND UNKNOWN PRIMARY
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-004148-35 Sponsor Protocol Number: EMR 200037-014 Start Date*: 2010-04-19
    Sponsor Name:Merck KGaA
    Full Title: Cilengitide and cetuximab in combination with platinum-based chemotherapy as first-line treatment for subjects with advanced NSCLC. Open-label, randomized, controlled, multicenter Phase II study in...
    Medical condition: Advanced non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) BE (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-014396-43 Sponsor Protocol Number: HN001 (TEMHEAD) Start Date*: 2010-02-09
    Sponsor Name:Medical School Hannover
    Full Title: A single arm, open-label multicenter phase II trial of temsirolimus in patients with relapsed/ recurrent squamous cell cancer of the Head and Neck (HNSCC)
    Medical condition: Patients with metastatic or local recurrenct squamous carcinoma of the head and neck (HNSCC) who have measurable progressive disease after platinum-based radiochemotherapy or recurrence or metastat...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004910-33 Sponsor Protocol Number: PAZOTEST-01 Start Date*: 2012-12-24
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Phase II study of single-agent Pazopanib (Votrient) for patients with relapsed or refractory germ-cell tumors (GCT).
    Medical condition: Testicular or extragonadal germ cell tumors.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10018187 Genitourinary neoplasms malignancy and gender unspecified HLT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014383-18 Sponsor Protocol Number: CRAD001CDE21T Start Date*: 2010-08-12
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: A single arm, open-label multicenter phase II trial of everolimus in patients with relapsed/refractory germ cell cancer
    Medical condition: Germ cell tumor, metastatic, relapsed or refractory
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055103 Testicular cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001915-52 Sponsor Protocol Number: A6181087 Start Date*: 2008-01-08
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, 10017
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED PHASE 3, EFFICACY AND SAFETY STUDY OF SUNITINIB (SU011248) IN PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER TREATED WITH ERLOTINIB
    Medical condition: Locally advanced or metastatic non small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Completed) HU (Prematurely Ended) AT (Completed) DK (Prematurely Ended) IT (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended) GR (Prematurely Ended) SK (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-000781-37 Sponsor Protocol Number: NKV102549 Start Date*: 2006-07-24
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagon...
    Medical condition: Chemotherapy induced nausea and vomiting (CINV) due to Moderately Emetogenic Chemotherapy (MEC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) IE (Completed) SK (Completed) ES (Completed) AT (Completed) EE (Completed) CZ (Completed) LT (Completed) HU (Completed) DK (Completed) LV (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004440-12 Sponsor Protocol Number: CPKC412A2408 Start Date*: 2017-11-12
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of midostaurin (PKC412) in patients 18 years of age or older with newly-diagnosed FLT3-mutated Acute Myeloid Leukemia ...
    Medical condition: newly diagnosed FLT3 mutated acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) CZ (Completed) ES (Ongoing) HU (Completed) FR (Completed) BG (Completed) GR (Completed) SK (Completed) LT (Completed) IT (Completed) EE (Completed) HR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-000880-27 Sponsor Protocol Number: CLBH589B2201 Start Date*: 2007-02-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase II Study Of Oral LBH589 In Adult Patients With Refractory Cutaneous T-Cell Lymphoma
    Medical condition: Adult patients with stages IB to IVA mycosis fungoides (MF) or Sézary syndrome (SS). All patients must have received at least two prior treatment regimens for their MF or SS, at least one of whic...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011679 Cutaneous T-cell lymphoma refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) HU (Completed) BE (Completed) DE (Completed) FR (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-000815-25 Sponsor Protocol Number: H3E-MC-JMGX Start Date*: 2005-03-22
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A randomized phase 3 study of two doses of ALIMTA in patients with locally advanced or metastatic Non-Small Cell Lung Cancer who have failed a prior platinum-containing chemotherapy.
    Medical condition: Patients with locally advanced or metastatic Non-Smal Cell Lung Cancer who have failed a prior Platinum-containing chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10059515 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-005536-32 Sponsor Protocol Number: CY503C2 Start Date*: 2009-04-30
    Sponsor Name:Cytavis Biopharma GmbH
    Full Title: Phase II double-blind placebo-controlled trial of CY-503 in patients with chemotherapy-refractory metastatic colorectal cancer
    Medical condition: Patients with chemotherapy-refractory metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-003439-18 Sponsor Protocol Number: D0810C00019 Start Date*: 2009-02-20
    Sponsor Name:AstraZeneca AB
    Full Title: Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or mor...
    Medical condition: platinum sensitive serous ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) PL (Completed) CZ (Completed) ES (Completed) EE (Completed) FR (Completed) AT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-002219-42 Sponsor Protocol Number: BCX1777-108 Start Date*: 2009-01-26
    Sponsor Name:Mundipharma Research Limited
    Full Title: A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children with Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin’s Lymphoma
    Medical condition: T-cell or B-cell precursor (BCP) acute lymphoblastic leukaemia (T-ALL or BCP-ALL) or T-cell Non Hodgkin’s lymphoma (T-NHL)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000844 Acute lymphoblastic leukaemia LLT
    9.1 10025321 Lymphomas non-Hodgkin's T-cell HLGT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) AT (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003175-45 Sponsor Protocol Number: TRIO 016 Start Date*: 2009-01-12
    Sponsor Name:Cancer International Research Group
    Full Title: A randomized phase II, open-label multicenter trial of panobinostat monotherapy in women with HER2 positive locally recurrent or metastatic breast cancer
    Medical condition: HER-2 positive locally recurrent or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) BE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000936-42 Sponsor Protocol Number: GENE-REPAIR Start Date*: 2008-05-13
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: DNA repair gene expression levels in NSCLC patients treated with platinum based chemotherapy: an open label randomized phase II study
    Medical condition: PATIENTS WITH NSCLC CANCER
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001472-38 Sponsor Protocol Number: APR-407 Start Date*: 2013-12-12
    Sponsor Name:Aprea Therapeutics AB
    Full Title: PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin/Pegylated Liposomal Doxorubicin Combination Chemotherapy With or Withou...
    Medical condition: Recurrent high grade serous ovarian carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000021045 10033131 Ovarian carcinoma LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) GB (Completed) SE (Completed) ES (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 19:45:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA